Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

* INCLUSION CRITERIA: * Must have any of the following: * one or more adrenal masses on CT and/or MRI and biochemical evidence of excess aldosterone OR --ACTH-independent hypercortisolism, with or without adrenal masses on CT and/or MRI OR * history of ACTH-dependent hypercortisolism (with or without adrenal enlargement) * Co-enrollment in 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial. * Age \>=18 years. * ECOG performance status \<= 2. * Women of child-bearing potential (WOCBP) and men must agree to use an effective contraception (barrier, hormonal, intrauterine device \[IUD\], surgical sterilization, abstinence) for two weeks prior to \[68Ga\]Ga-PentixaFor scan and for one week after the \[68Ga\]Ga-PentixaFor scan. * Breastfeeding should be discontinued for one week after the \[68Ga\]Ga-PentixaFor scan. * Men must agree not to donate sperm for one week after the \[68Ga\]Ga-PentixaFor scan. * Participants must be able to understand and willing to sign a written informed consent document. EXCLUSION CRITERIA: * Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening. * Uncontrolled intercurrent illness or social situations based on the review of medical history that would limit compliance with study requirements. * Contraindications to having an MRI and CT.